Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07541430Phase 2Recruiting

A Study in Adults With Desmoid Tumors

Role: lead

NCT06623136Phase 2Recruiting

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Role: lead

NCT05717348Phase 1Active Not Recruiting

A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours

Role: lead

NCT06543056Phase 2Recruiting

A Study of ES014 in Subjects With Advanced Solid Tumors

Role: collaborator

NCT05167448Phase 1Active Not Recruiting

A Study of ES104 in Patients With Metastatic Colorectal Cancer

Role: lead

All 5 trials loaded